| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.24▼ | 1.13▲ | 1.05▲ | 1.00▲ | 1.06▲ |
| MA10 | 1.23▼ | 1.04▲ | 0.99▲ | 1.01▲ | 1.10▲ |
| MA20 | 1.15▲ | 0.98▲ | 0.96▲ | 1.04▲ | 1.30▼ |
| MA50 | 1.03▲ | 0.96▲ | 0.98▲ | 1.12▲ | 1.77▼ |
| MA100 | 0.97▲ | 0.98▲ | 1.01▲ | 1.35▼ | 3.52▼ |
| MA200 | 0.96▲ | 1.02▲ | 1.05▲ | 1.70▼ | 3.47▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.003▲ | 0.036▲ | 0.033▲ | 0.011▲ | 0.034▲ |
| RSI | 70.223▲ | 82.507▲ | 80.999▲ | 60.584▲ | 44.438▼ |
| STOCH | 75.449 | 81.795▲ | 89.583▲ | 32.342 | 39.592 |
| WILL %R | -27.273 | -16.484▲ | -14.848▲ | -14.815▲ | -37.273 |
| CCI | 41.980 | 162.097▲ | 287.093▲ | 240.765▲ | 23.072 |
| ▲ PSAR&MOM | $HUMA PSAR Switch Up + Momentum | Set Alert |
| ▲ RSI&MACD | $HUMA MACD cross and RSI above 55 | Set Alert |
| ▲ RSI&VOL | $HUMA RSI Cross Up and Volume | Set Alert |
| RSI | $HUMA RSI(14) Crossed Above 50 | Set Alert |
| ▲ MACD | $HUMA MACD(12,26,9) Crossed Above Signal Line | Set Alert |
| MA | $HUMA Price Crossed Above MA(50) | Set Alert |
| MA | $HUMA Price Crossed Above MA(26) | Set Alert |
| MA | $HUMA Price Crossed Above MA(13) | Set Alert |
| MA | $HUMA Price Crossed Above MA(7) | Set Alert |
| ▲ GAP | $HUMA Open Gap Up %5 | Set Alert |
| ▲ GAP | $HUMA Open Gap Up %3 | Set Alert |
| ▲ GAP | $HUMA Open Gap Up %2 | Set Alert |
| ▲ BREAK | $HUMA Price Breaks 10 Days High | Set Alert |
|
Monday, February 09, 2026 05:18 AM
Humacyte’s Symvess® is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA).
|
|
Wednesday, December 10, 2025 11:26 AM
Humacyte, Inc. (NASDAQ:HUMA) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. In mid-November, Benchmark analyst Bruce Jackson maintained a Buy rating on Humacyte, Inc.
|
|
Sunday, November 16, 2025 04:00 PM
As of November 17, 2025, the average one-year price target for Humacyte is $8.01/share. The forecasts range from a low of $3.03 to a high of $26.25. The average price target represents an increase of ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 09/02/26 | 1.015 | 1.285 | 1.015 | 1.225 | 13,195,914 |
| 06/02/26 | 0.9278 | 0.9579 | 0.902 | 0.9383 | 2,435,572 |
| 05/02/26 | 0.96 | 0.9638 | 0.88 | 0.8862 | 4,082,001 |
| 04/02/26 | 0.9902 | 1.00 | 0.93 | 0.9582 | 3,409,282 |
| 03/02/26 | 1.01 | 1.027 | 0.97 | 0.999 | 2,935,405 |
| 02/02/26 | 0.9995 | 1.02 | 0.9508 | 1.02 | 3,100,558 |
| 30/01/26 | 1.02 | 1.06 | 0.9844 | 0.9977 | 3,070,497 |
| 29/01/26 | 1.01 | 1.0499 | 0.975 | 1.03 | 2,693,529 |
| 28/01/26 | 1.04 | 1.05 | 0.981 | 1.00 | 3,173,774 |
| 27/01/26 | 1.03 | 1.035 | 0.97 | 1.03 | 3,829,539 |
|
|
||||
|
|
||||
|
|